10-K: Akoya Biosciences Reports Full Year 2023 Results, Highlights Growth in Spatial Biology Market

Akoya Biosciences, a leader in spatial biology, announced its full year 2023 results, showcasing a 29% revenue increase and a 27% expansion of its installed instrument base.

Summary

• Akoya Biosciences reported a total revenue of $96.6 million for the year ended December 31, 2023, compared to $74.9 million in 2022, representing a 29% increase.
• The company's installed base of instruments grew by 27% year-over-year, reaching 1,183 instruments as of December 31, 2023.
• Akoya incurred a net loss of $63.3 million in 2023, an improvement from the $70.6 million net loss in 2022.
• The company's spatial biology solutions are used in discovery, translational, and clinical research, with applications in oncology, immunology, and neuroscience.
• Akoya's PhenoCycler and PhenoImager platforms offer end-to-end solutions for spatial phenotyping, enabling researchers to map cell types and biomarkers in tissue samples at single-cell resolution.
• The spatial biology market is estimated to be approximately $14 billion, with Akoya primarily targeting the $7 billion discovery and translational research segments.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While there is strong revenue growth and expansion of the installed base, the company is still incurring significant losses and faces numerous risks. The sentiment is cautiously optimistic, with a focus on the company's growth potential but also acknowledging the challenges ahead.

Positives

• Akoya is an established leader in the spatial biology market with a strong competitive position.
• The company offers comprehensive solutions that address the entire continuum from discovery to clinical research.
• Akoya has strong relationships with leading biopharma and life science tools companies, top research institutions, and medical centers.
• The company's management team has extensive industry experience.
• Akoya is investing in new applications, content development, and workflow improvements to drive pull-through revenue.
• The company is forming analysis software partnerships to accelerate discovery.
• Akoya is investing in clinical developments to demonstrate validity.
• The company has a CLIA certified lab, which is an important step towards advancing the company's platforms toward clinical use.

Negatives

• Akoya has incurred significant losses since inception and expects to incur losses in the future.
• The company's operating results have fluctuated significantly in the past and may fluctuate significantly in the future.
• The company relies on third-party manufacturers, making it vulnerable to supply shortages and price fluctuations.
• The company faces significant competition in its market.
• The company may need to raise additional capital to fund its operations.
• The company's Midcap Trust Term Loan contains covenants that restrict its operating activities.

Risks

• The company may not be able to generate sufficient revenue to achieve and maintain profitability.
• The company's products may not continue to gain market acceptance.
• The company may fail to enter into new customer relationships or maintain and expand existing relationships.
• The company's operating results may fluctuate significantly in the future.
• The company's limited operating history makes it difficult to evaluate its future prospects.
• Acquisitions could disrupt the company's business and cause dilution to its stockholders.
• The company's products may fail to achieve and sustain sufficient scientific acceptance.
• The company may be sued for product liability.
• The company's business may be harmed if its customers discontinue or spend less on research.
• The company may be unable to support demand for its products.
• The sizes of the markets for the company's solutions may be smaller than estimated.
• The company may fail to offer high-quality customer service.
• The company may need to raise additional capital.
• The company's Midcap Trust Term Loan contains restrictive covenants.
• The company's actual operating results may differ significantly from any operating guidance it may provide.
• The company faces significant competition.
• The company must develop new products and service offerings to remain competitive.
• The company may be unable to manage its future growth effectively.
• The company has limited experience in marketing and sales.
• The company relies on distributors for sales outside the United States.
• The loss of any member of the company's senior management team could adversely affect its business.
• The company may expend resources on markets that do not yield meaningful revenue.
• The company's operating facilities could become damaged or inoperable.
• The company's insurance policies may not protect it from all business risks.
• Security incidents could compromise information related to the company's business.
• Seasonality may cause fluctuations in the company's revenue and results of operations.
• Public health crises could cause disruptions to the company's business.
• The company relies on third-party manufacturers and suppliers.
• The company's third-party manufacturers may fail to manufacture finished goods on a timely basis.
• The company's forecasts may be incorrect.
• The company's RUO products may be subject to additional government regulations.
• The company may be subject to additional data privacy and security laws.
• The company's international expansion exposes it to various risks.
• The company could be adversely affected by violations of the FCPA.
• Unfavorable economic conditions could adversely affect the company's business.
• The company's employees may engage in misconduct.
• The company uses biological and hazardous materials.
• The company may be unable to obtain and maintain sufficient intellectual property protection.
• The company depends on intellectual property licensed from third parties.
• Changes in patent law could diminish the value of the company's patents.
• Issued patents could be found invalid or unenforceable.
• The company may be subject to claims challenging the ownership or inventorship of its intellectual property.
• The company may become involved in intellectual property litigation.
• The company may not be able to protect and enforce its trademarks and trade names.
• The company may be subject to claims that its employees have wrongfully used trade secrets.
• The company's use of open-source software could adversely affect its ability to offer its products.
• The market price of the company's common stock is likely to continue to be volatile.
• Securities analysts may not publish favorable research or reports about the company.
• The company is an emerging growth company and a smaller reporting company, which may make its stock less attractive to investors.
• The company's estimates or judgments relating to its critical accounting policies may be incorrect.
• Future sales and issuances of the company's common stock could result in additional dilution.
• The company does not intend to pay dividends for the foreseeable future.
• The company's directors, officers, and principal stockholders have significant voting power.
• The company will incur increased costs as a result of operating as a public company.
• The company's ability to use its net operating losses and certain other tax attributes may be limited.
• Provisions in the company's corporate charter documents and under Delaware law could make an acquisition of the company more difficult.
• Claims for indemnification by the company's directors and officers may reduce its available funds.
• The company's amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for certain disputes.

Future Outlook

The company expects to continue to incur operating losses for the foreseeable future but plans to improve results of operations in an effort to achieve cash flow positivity. Akoya plans to continue to grow its business while improving results of operations by attracting and retaining qualified personnel, marketing and selling new and existing solutions and services, investing in processes and infrastructure to scale its business, supporting research and development to introduce new solutions, expanding, protecting and defending its intellectual property, and acquiring complementary businesses or technologies to support the growth of its business.

Management Comments

• The company believes it is the only business with the breadth of platform capabilities that enable researchers to do a deep exploratory and discovery study, and then further advance and scale their research through the translational and clinical phases.
• The company also believes that it is the only spatial biology business that is capable of delivering a menu of clinical IVD tests on its platform for routine diagnostic testing.

Industry Context

The spatial biology market is rapidly evolving and is becoming a key area of focus for researchers and clinicians. Akoya is positioned as a leader in this market, offering solutions that address the needs of researchers across the continuum from discovery through clinical research and diagnostics. The company's partnerships with leading biopharma and life science tools companies demonstrate the growing importance of spatial biology in drug development and precision medicine.

Comparison to Industry Standards

• Akoya's 29% revenue growth is strong compared to the broader life sciences tools market, which is experiencing more moderate growth.
• The 27% increase in installed base is a key indicator of future recurring revenue, which is a common metric for companies in this sector.
• The 50% increase in peer-reviewed publications highlights the growing scientific validation of Akoya's technology, which is a critical factor for adoption in the life sciences industry.
• Competitors like 10x Genomics and Nanostring Technologies also operate in the single-cell analysis space, but Akoya differentiates itself with its focus on spatial context and its end-to-end solutions.
• The CLIA certification of Akoya's ABS lab positions it well to compete in the clinical diagnostics market, which is a key growth area for the company.

Management Changes

Corporate Governance

Related Party Transactions

• The company incurred costs of goods sold of approximately $7,581 and $5,684, respectively, related to sales of consumables manufactured by Argonaut Manufacturing Services Inc. (AMS), a portfolio company of Telegraph Hill Partners, which holds greater than 5% of the company's total outstanding shares.

Stakeholder Impact

• Shareholders may experience volatility in the stock price due to the company's financial performance and market conditions.
• Employees may be affected by changes in the company's operations and strategic direction.
• Customers will benefit from the company's continued investment in new applications and workflow improvements.
• Suppliers may be affected by changes in the company's supply chain and manufacturing processes.
• Creditors may be affected by the company's debt obligations and financial performance.

Next Steps

• The company intends to leverage sales and marketing efforts to drive adoption of its solutions.
• The company plans to invest in new applications, content development, and workflow improvements.
• The company will continue to form analysis software partnerships to accelerate discovery.
• The company will continue to invest in clinical developments to demonstrate validity.

Key Dates

Keywords

spatial biology, phenotyping, biomarkers, immuno-oncology, cancer research, single-cell analysis, tissue analysis, diagnostics, clinical research, drug development, genomics, proteomics, multiplex immunofluorescence, companion diagnostics, research tools